Company profile
Kiora Pharmaceuticals, Inc.
NASDAQ: KPRX · Healthcare · Biotechnology
PublicHQ Encinitas, UTCIK 0001372514Reports USD
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
52DFH 49DQ 58GM 50SS 44
v0.1 · 65/100 weight · provisional
↑ growth stability, balance-sheet leverage · ↓ revenue growth (YoY), workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$10.8M
Employees
13
as of 2026-09-20
Market cap
$12.2M
as of 2026-09-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$10.8M-$10.8M2025
Operating income-$12.8M-$12.8M2025
Total assets$24.3M$24.3M2025
Liabilities$8.1M$8.1M2025
Equity$16.1M$16.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY19
FY20
FY21
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kiora Pharmaceuticals, Inc.’s revenue?
Kiora Pharmaceuticals, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Quoin Pharmaceuticals, Ltd.37DLobe Sciences Ltd.43DSynlogic, Inc.45DIzotropic Corporation——Satellos Bioscience Inc.——Phio Pharmaceuticals Corp.41DKey facts
CEOBrian Strem
SectorHealthcare
IndustryBiotechnology
HeadquartersEncinitas, UT
ExchangeNASDAQ: KPRX
Employees13
IPO date2015-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.